The U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to NEXTBIOMEDICAL CO., LTD for its Nexsphere-F embolic microsphere. This approval paves the way for the RESORB trial, a multi-center, randomized, open-label study designed to evaluate the safety and efficacy of Nexsphere-F in treating knee osteoarthritis (OA) through genicular artery embolization (GAE).
The RESORB trial will enroll participants across various healthcare institutions in the United States. The study will assess Nexsphere-F's ability to alleviate pain and improve mobility in patients suffering from OA-related symptoms. The GAE approach aims to provide a more sustainable and patient-friendly treatment option compared to existing therapies.
Nexsphere-F: A Novel Approach to Osteoarthritis Treatment
Nexsphere-F is composed of a hydrophilic material designed for endovascular embolization procedures. Upon injection, the microspheres block target blood vessels, temporarily cutting off blood supply to the tissues. The unique characteristic of Nexsphere-F is its complete resorption by the body over time, which minimizes the risk of complications and ensures biocompatibility.
Dr. Ziv J Haskal, Professor of Interventional Radiology at the University of Virginia and national Principal Investigator for RESORB, highlighted Nexsphere-F's prior success: "Nexsphere-F has already received CE-MDD approval for use in arthritis embolization and has proven its superior safety and efficacy in thousands of musculoskeletal embolization patients in Asia and Europe."
Addressing an Unmet Need in Osteoarthritis Care
Knee osteoarthritis is a prevalent and debilitating condition, affecting over 654 million individuals aged 40 and above worldwide. This makes it a leading cause of pain and disability among older adults. Current treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and hyaluronic acid injections, often provide only temporary relief and are associated with significant side effects and limited long-term efficacy.
The RESORB trial and Nexsphere-F represent a significant step towards addressing these unmet needs by offering a potentially more effective and sustainable solution for managing knee osteoarthritis. The company is actively securing clinical trial sites for the pivotal U.S. study.
Company Vision
CEO Dr. Don Haeng Lee emphasized the significance of the FDA approval, stating it reflects the company's commitment to advancing innovative medical solutions. He expressed optimism that the RESORB clinical trial will proceed seamlessly, paving the way for timely FDA approval and the global availability of Nexsphere-F to improve the quality of life for arthritis patients worldwide.
